The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments

Indian Journal of Psychiatry

Volumn 51, Issue 1, 2009, Pages 12-25

  Andrade, Chittaranjan ^a   Radhakrishnan, Rajiv ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Alzheimer's disease; Cognition; Dementia; Mild cognitive impairment; Zlderly

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIHYDROERGOTOXINE MESILATE; DIMEBON; DONEPEZIL; ETANERCEPT; GALANTAMINE; GINKGO BILOBA EXTRACT; GROWTH HORMONE SECRETAGOGUE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTAMOREN; LITHIUM; MEMORIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NAOHUANDAN; NOOTROPIC AGENT; OMEGA 3 FATTY ACID; PBT 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRACETAM; PLACEBO; RIVASTIGMINE; TARENFLURBIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN VENTRICLE PERITONEUM SHUNT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; DAILY LIFE ACTIVITY; DEMENTIA; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXERCISE; FISH; FOOD INTAKE; FRUIT; GASTROINTESTINAL SYMPTOM; HERBAL MEDICINE; HUMAN; INCIDENCE; LIFESTYLE; MEMORY DISORDER; MENINGOENCEPHALITIS; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; MUSCLE CRAMP; NONHUMAN; PEROXISOME; REVIEW; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; STROKE; TEA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE INCONTINENCE; VEGETABLE;

EID: 77649336371     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.44900     Document Type: Review

References (89)

1. Kokmen E, Beard CM, O'Brien PC, Offord KP, Kurland LT. Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984). Neurology 1993;43:1887-92.
2. Drachman DA. If we live long enough, will we all be demented? Neurology 1994;44:1563-65.
3. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29:125-32.
4. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7.
5. Vas CJ, Pinto C, Panikker D, Noronha S, Deshpande N, Kulkarni L, et al. Prevalence of dementia in an urban Indian population. Int Psychogeriatr 2001;13:439-50.
6. Shaji S, Bose S, Verghese A. Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry 2005;186:136 -40.
7. Rajkumar S, Kumar S, Thara R. Prevalence of dementia in a rural setting - a report from India. Int J Geriatr Psychiatry 1997;12:702-7.
8. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
9. Morris JC. Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol 2006;63:15-6.
10. Petersen RC, O'Brien J. Mild cognitive impairment should be considered for DSM-V. J Geriatr Psychiatry Neurol 2006;19:147-54.
11. Ikeda M. Nippon Ronen Igakkai Zasshi. Epidemiology of Mild Cognitive Impairment (MCI) among the community-dwelling elderly-findings from the Nakayama study. Nippon Ronen Igakkai Zasshi 2004;41:186-8.
12. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004;63:115-21.
13. Palmer K, Bäckman L, Winblad B, Fratiglioni L. Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry 2008;16:603-11.
14. Das SK, Bose P, Biswas A, Dutt A, Banerjee TK, Hazra AM, et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 2007;68:2019-26.
15. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD005593.
16. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005;62:1849-53.
17. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and omega-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-6.
18. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al, Benefits of fatty fish on dementia risk are stronger for those without ApoE epsilon4. Neurology 2005;65:1409-14.
19. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am J Med 2006;119:751-9.
20. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007;69:1921-30.
21. Nurk E, Drevon CA, Refsum H, Solvoll K, Vollset SE, Nygerd O, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 2007;86:1470-8.
22. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007;85:1142-7.
23. Dullemeijer C, Durga J, Brouwer IA, van de Rest O, Kok FJ, Brummer RJ, et al. Omega-3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 2007;86:1479-85.
24. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007;85: 1103-11.
25. Ng TP, Feng L, Niti M, Kua EH, Yap KB. Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr 2008;88:224-31.
26. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:112-7.
27. Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E, Bianchin M, et al. Physical activity and dementia risk in the elderly: findings a prospective Italian study. Neurology 2008;70:1786-94.
28. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73-81.
29. Stranahan AM, Khalil D, Gould E. Running induces widespread structural alterations in the hippocampus and entorhinal cortex. Hippocampus 2007;17:1017-22.
30. Lange-Asschenfeldt C, Kojda G. Alzheimer's disease, cerebrovascular dysfunction and the benefits of exercise: From vessels to neurons. Exp Gerontol 2008;43:499-504.
31. van Uffelen JG, Chinapaw MJ, van Mechelen W, Hopman-Rock M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br J Sports Med 2008;42:344-51.
32. Forbes D, Forbes S, Morgan DG, Markle-Reid M, Wood J, Culum I. Physical activity programs for persons with dementia. Cochrane Database Syst Rev 2008;3:CD006489.
33. Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A 2001;98:3440-5.
34. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002;287:742-8.
35. Ball K, Berch DB, Helmers KF, Jobe JB, Leveck MD, Marsiske M, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 2002;288:2271-81.
36. Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Koepke KM, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006;296:2805-14.
37. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
38. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008;5:416-21.
39. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008;71:344-50.
40. Lichtenthaler SF, Haass C. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004;113:1384-7.
41. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047-51.
42. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217-24.
43. Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003;73:261-9.
44. Muñoz-Montaño JR, Lim F, Moreno FJ, Avila J, Díaz-Nido J. Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease. J Alzheimers Dis 1999;1:361-78.
45. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A, et al. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 1999;45:995-1003.
46. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423:435-9.
47. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007;190:359-60.
48. Kessing LV, Søndergård L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008;65:1331-5.
49. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005;19:20-2.
50. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007;2:CD003120. Review.
51. Dodge HH, Zitzelberger T, Oken BS, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 2008;70:1809-17.
52. McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008;23:1222-30.
53. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300:2253-62.
54. Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E, Mangialasche F, et al. Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr 2008;87:1306-13.
55. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.
56. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2008;3:CD002854.
57. Greenaway MC, Hanna SM, Lepore SW, Smith GE. A behavioral rehabilitation intervention for amnestic mild cognitive impairment. Am J Alzheimers Dis Other Demen 2008;23:451-61.
58. Hampstead BM, Sathian K, Moore AB, Nalisnick C, Stringer AY. Explicit memory training leads to improved memory for face-name pairs in patients with mild cognitive impairment: results of a pilot investigation. J Int Neuropsychol Soc 2008;14:883-9.
59. Kurz A, Pohl C, Ramsenthaler M, Sorg C. Cognitive rehabilitation in patients with mild cognitive impairment. Int J Geriatr Psychiatry 2008;Jul 17. [Epub ahead of print]
60. Galante E, Venturini G, Fiaccadori C. Computer-based cognitive intervention for dementia: preliminary results of a randomized clinical trial. G Ital Med Lav Ergon 2007;29:B26-32.
61. Talassi E, Guerreschi M, Feriani M, Fedi V, Bianchetti A, Trabucchi M. Effectiveness of a cognitive rehabilitation program in mild dementia (MD) and mild cognitive impairment (MCI): a case control study. Arch Gerontol Geriatr 2007;44:391-9.
62. Christensen DD. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. Prim Care Companion J Clin Psychiatry 2007;9:32-41.
63. Christensen DD. Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr 2007;12:113-116, 119-23.
64. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gammasecretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8.
65. Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2008;7:805-11.
66. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting A-beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779-86.
67. Griffin WS. Perispinal etanercept: Potential as an Alzheimer therapeutic. J Neuroinflammation 2008;5:3.
68. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008;5:2.
69. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93.
70. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007;21:292-9.
71. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62.
72. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: followup of a randomised, placebo-controlled phase I trial. Lancet 2008;372: 216-23.
73. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008;71:1702-8.
74. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-14.
75. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev 2001;2:CD000359.
76. Vernon MW, Sorkin EM. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1991;1:17-35.
77. Grigor'ev VV, Dranyi OA, Bachurin SO. Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons. Bull Exp Biol Med 2003;136:474-7.
78. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003;993:334-44.
79. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372: 207-15.
80. Andrade C, Sudha S, Venkataraman BV. Herbal treatments for ECSinduced memory deficits: a review of research and a discussion on animal models. J ECT 2000;16:144-56.
81. Meng RS, Li QM, Wei CX, Chen B, Liao HY, Zhou YT. Clinical observation and mechanism study on treatment of senile dementia with Naohuandan. Chin J Integr Med 2005;11:111-6.
82. Zhou RQ, Lin SM, Yuan Q. Clinical study on effect of shenyin oral liquid in treating mild cognitive impairment. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007;27:793-5.
83. Wang XM, Fu H, Liu GX, Zhu W, Li L, Yang JX. Effect of modified wuzi yanzong granule on patients with mild cognitive impairment from oxidative damage aspect. Chin J Integr Med 2007;13:258-63.
84. Andrade C, Gowda S, Chaturvedi SK. Treatment of age-related cognitive decline with a herbal formulation: A double-blind study. Indian J Psychiatry 1998;40:240-6.
85. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, OldeRikkert MG, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008;71:430-8.
86. Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, et al. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: Results from a randomized, placebo-controlled trial. Psychiatry Res 2008;161:284-91.
87. Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, et al. Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology 2002;59:1139-45.
88. Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D. Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study. Neurology 2008;71:202-9.
89. Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008;56:847-53.